Specialised products for patients with rare and inherited metabolic disorders.
We develop and commercialise medicines, medical nutrition and medical foods through focused R&D, orphan pathways and targeted regional partnerships.
Programmes being advanced across discovery, clinical and commercialisation.
A focused portfolio of medicines, medical nutrition and medical foods for rare and inherited metabolic disorders.
- MetaCore TyrosinaemiaDietary management of tyrosinaemiaTyrosinaemia type 1
- MetaCore PKUDietary management of PKUPhenylketonuria (PKU)
- MH-910Selected fatty acid oxidation indicationFatty acid oxidation disorders
- MetaCore MSUDDietary management of MSUDMaple syrup urine disease (MSUD)
- MH-101Adjunctive management of hyperammonaemiaUrea cycle disorders
- MetaFuel MMADietary management of MMAMethylmalonic acidaemia (MMA)
MetaCore Tyrosinaemia
Dietary management of tyrosinaemia
Tyrosinaemia type 1
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
MetaCore PKU
Dietary management of PKU
Phenylketonuria (PKU)
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
MH-910
Selected fatty acid oxidation indication
Fatty acid oxidation disorders
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
MetaCore MSUD
Dietary management of MSUD
Maple syrup urine disease (MSUD)
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
MH-101
Adjunctive management of hyperammonaemia
Urea cycle disorders
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
MetaFuel MMA
Dietary management of MMA
Methylmalonic acidaemia (MMA)
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Marketed
- Discovery
- Formulation
- Preclinical
- Clinical
- Regulatory
- Commercial
Programmes shown are at various stages of development or commercialisation. Statements do not constitute claims of efficacy, superiority or regulatory certainty. See full disclaimer.
Three product categories. One disciplined approach.
Meta Healthcare operates across medicines, medical nutrition and medical foods — advancing differentiated products through efficient and disciplined development pathways.
- 01
Medicines
Specialised therapies advanced through focused development and orphan pathways for underserved metabolic indications.
- 02
Medical nutrition
Differentiated formulations designed to support patients managing rare and inherited metabolic disorders.
- 03
Medical foods
Reformulated and clinically appropriate products built for adoption across NHS and partner-region settings.
Building durable value across territories.
Our model combines reformulation, orphan pathways and regional licensing to advance specialised products with retained long-term value in key territories.
Reformulation
Improving on existing products to address unmet metabolic patient needs and adoption barriers.
Orphan pathways
Pursuing orphan designations in the FDA, EMA and MHRA to support development of rare disease programmes.
Regional licensing
Retained long-term value in key territories through structured licensing collaborations.
Targeted partnerships
Working with regional specialists to extend access where local expertise is decisive.
Regional licensing and co-development opportunities across our pipeline.
We work with regional specialists to extend access, accelerate registration and commercialise specialised products in territories where local expertise is decisive.
Considering a partnership? Start with the routes overview, or send us a message directly.
